Innovative Metabolics

Innovative Metabolics is a private, clinical-stage biotechnology company based in New York, focused on developing novel oral therapies for metabolic disorders. The company's lead candidate, IM-101, is a proprietary fixed-dose combination of two FDA-approved small molecules designed to provide synergistic effects on weight loss and glycemic control. By leveraging the established safety profiles of its constituent drugs, Innovative Metabolics aims to offer a safer, more tolerable, and cost-effective oral alternative to current injectable GLP-1 receptor agonists. The company is led by Dr. Hassan Heshmati, a veteran endocrinologist with extensive experience in global pharmaceutical research and development.